Senores Pharmaceuticals will host an investor conference on September 2, 2026, at 11:00 am IST in Mumbai. The event is organized by Elara Capital and will feature both group and one-on-one meetings with company officials.

The interactions are scheduled to take place in a physical format at the Mumbai venue. Company representatives will engage with institutional investors and analysts during the session.

Meeting Details

Regulatory Disclosure

The disclosure was made pursuant to Regulation 30(6) read with Schedule III of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements), Regulations, 2015. The company confirmed that discussions will be based solely on publicly available information.

No unpublished price sensitive information (UPSI) is intended to be discussed during these interactions. The company noted that changes to the schedule may occur due to exigencies on the part of the host or the company.

Shilpa Sharma, Company Secretary and Compliance Officer of Senores Pharmaceuticals Limited, signed the intimation filed with the Bombay Stock Exchange and the National Stock Exchange of India Limited.

Senores Pharmaceuticals Limited has approved the incorporation of wholly owned subsidiaries in Mexico and Canada to expand its international distribution network. The Board also approved the Senores Pharmaceuticals Employee Stock Option Scheme 2026 (ESOS 2026) to incentivize key talent.

The strategic moves were approved during a Board meeting held on August 26, 2026. The company aims to support its business objectives in the Mexican and Canadian markets through these new entities. Additionally, the Board appointed Mrs. Shilpa Sharma as Company Secretary and Compliance Officer, effective August 26, 2026.

International Expansion Plans

The company plans to incorporate a Wholly Owned Subsidiary (WOS) in Mexico. This entity will undertake the supply and distribution of pharmaceutical products in the Mexican market. Senores will subscribe to 100% of the initial paid-up share capital of this WOS in cash.

Similarly, the Board approved the incorporation of a subsidiary in Canada. This entity will focus on the supply and distribution of pharmaceutical products in the Canadian market. The investment will be made either directly or through its existing WOS, with Senores holding 51% or more of the initial paid-up share capital.

Employee Stock Option Scheme 2026

The Board approved the ESOS 2026, subject to shareholder approval. The scheme covers 472,000 employee stock options, representing 1% of the existing equity on a fully diluted basis. Each option, when exercised, will convert into one equity share of face value ₹10.

Key terms of the scheme include:

• Vesting period: Minimum 1 year, maximum 4 years from grant date.
• Exercise period: Maximum 4 years from vesting date.
• Pricing: Exercise price determined by the Nomination and Remuneration Committee, with a discount of up to 50% from the market price on the grant date.
• Per-employee limit: Maximum 118,000 options per employee under this scheme.

Board Appointments

The Board appointed Dr. Viranchi Arvindbhai Shah as an Additional Non-Executive Independent Director, effective August 26, 2026. He will hold office until the ensuing Annual General Meeting. Dr. Shah brings over 25 years of experience in the pharmaceutical sector and serves as the National Spokesperson of the Indian Drug Manufacturers' Association (IDMA).

Mrs. Shilpa Sharma was appointed as Company Secretary and Compliance Officer. She is an Associate Member of the Institute of Company Secretaries of India with over 13 years of experience in corporate governance and listed-company compliances.